Nuo Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2026-01-26. 2 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Pittman Scott M. | 11.6% | 5,627,500 | SCHEDULE 13D/A, 2026-06-03 | 2026-05-29 |
| Jacobs Paul Anthony | 6.6% | 3,183,500 | SCHEDULE 13G/A, 2026-02-12 | 2026-01-23 |
Purpose of Transaction (Item 4)
Pittman Scott M.
Item 4 of this Schedule 13D is hereby amended as follows: On January 23, 2026, the closing (the "Initial Closing") occurred of a Loan and Security Agreement dated January 21, 2026 (the "Initial Loan Agreement") among the Company and certain lenders (including the Reporting Person). Upon the Initial Closing, the Reporting Person loaned $200,000 to the Company and, pursuant to the Initial Loan Agreement, committed to loaning $410,000 in a second funding, if requested by the Company, to be held on September 30, 2026 (a "Second Closing"). On May 29, 2026, the closing (the "Interim Closing") occurred of an Amended and Restated Loan and Security Agreement dated May 29, 2026 (the "Interim Loan Agreement") among the Company and certain lenders (including the Reporting Person). The Interim Loan Agreement amended and restated the Initial Loan Agreement. Upon the Interim Closing, the Reporting Person loaned $100,000 to the Company and, as amended pursuant to the Interim Loan Agreement, committed to loaning $100,000 in the Second Closing. At the Initial Closing, the Company issued a Secured Promissory Note (the "Initial Note") to each of the lenders (including the Reporting Person), at the Interim Closing, the Company issued a Secured Promissory Note (the "Interim Note") to each of the lenders (including the Reporting Person), and upon a Second Closing, if any, the Company will issue an additional Secured Promissory Note (a "Second Note") to each of the lenders (including the …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-03; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-26 | Pittman Scott M. | 11.6% | SCHEDULE 13D/A |
| 2026-02-12 | Jacobs Paul Anthony | 6.6% | SCHEDULE 13G/A |
| 2026-06-03 | Pittman Scott M. | 11.6% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Nuo Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.